Search clinical trials for: High-Risk Myelodysplastic Syndrome

Total 37427 results

Schrödinger, Inc.

Recruiting

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | High-Risk and Very High-Risk Myelodysplastic Syndromes

United States
University of British Columbia

Withdrawn

Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer (Rideau)

Bladder Cancer | High-Risk Cancer | Durvalumab | Non-muscle Invasive | Tremelimumab

Canada
University of Chicago

Terminated

The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
Joshua Woolley
Heffter Research Institute; Usona Institute; River Styx Foundation; Stupski Foundation

Completed

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

Depression | Distress | Grief

United States
M.D. Anderson Cancer Center

Completed

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Leukemia

United States
M.D. Anderson Cancer Center
GlaxoSmithKline

Terminated

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

Leukemia

United States
Merck Sharp & Dohme LLC

Completed

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)

Chronic Hepatitis C
Masonic Cancer Center, University of Minnesota
University of Minnesota

Withdrawn

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Treatment-Related Acute Myeloid Leukemia | High-Risk Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Eisai Inc.

Completed

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

Leukemia

United States
M.D. Anderson Cancer Center
Cephalon

Completed

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Leukemia

United States
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk

Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center

Completed

Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Leukemia | AML | MDS | CML

United States
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Pfizer; The Leukemia and Lymphoma Society

Terminated

A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

Refractory Acute Leukemia | Relapsed Acute Leukemia | High-Risk Myelodysplasia

United States
M.D. Anderson Cancer Center

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Sanofi

Terminated

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Novartis

Completed

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Phase II 5-Azacytidine Plus VPA Plus ATRA

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Masonic Cancer Center, University of Minnesota

Not yet recruiting

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Acquired Pure Red Cell Aplasia | Paroxysmal Nocturnal Hemoglobinuria | Severe Aplastic Anemia | Acquired Amegakaryocytic Thrombocytopenia
Novartis Pharmaceuticals

Not yet recruiting

Home Reported Outcomes in PNH

Paroxysmal Nocturnal Hemoglobinuria
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Not yet recruiting

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Relapsed Myelodysplastic Syndrome

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Janssen Research & Development, LLC

Not yet recruiting

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Myelofibrosis | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Hematologic Malignancy | Aplastic Anemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Bone Marrow Transplant Rejection | Acute Lymphoblastic Leukemia (ALL), Adult
Instituto de Investigación Biomédica de Salamanca
Carlos III Health Institute

Recruiting

Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA) (UMBRELLA-SUMMA)

Myelodysplastic Syndromes

Spain
Hangzhou GluBio Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of GLB-001 in Patients With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloid Malignancy

China
Apollo Therapeutics Ltd

Not yet recruiting

A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS

Myelodysplastic Syndrome With Excess Blasts | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Myelodysplastic Syndrome Acute Myeloid Leukemia
Byondis B.V.

Not yet recruiting

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

Relapsed / Refractory AML | Relapsed / Refractory MDS
OHSU Knight Cancer Institute
Oregon Health and Science University; Oryzon Genomics S.A.

Not yet recruiting

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome/Acute Myeloid Leukemia

United States
Imperial College London

Not yet recruiting

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial (MAST)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Lymphoblastic Leukaemia

United Kingdom
Northside Hospital, Inc.

Not yet recruiting

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Ruijin Hospital
Sun Yat-sen University; Shanghai Zhongshan Hospital; RenJi Hospital; Huashan Hospital and other collaborators

Recruiting

A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia

China
University of Alabama at Birmingham

Not yet recruiting

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

Myelodysplastic Syndromes | Myeloproliferative Disorders | Acute Leukemia | GVHD,Acute

United States
Alexion Pharmaceuticals, Inc.

Not yet recruiting

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Pregnancy | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Atypical Hemolytic Uremic Syndrome (aHUS) | Ultomiris-exposed Pregnant/ Postpartum | Generalized Myasthenia Gravis (gMG) | Neuromyelitis Optica Spectrum Disorder (NMOSD)
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes
National Cancer Institute (NCI)

Not yet recruiting

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Myelodysplastic Syndromes

United States
Remix Therapeutics

Recruiting

Study of REM-422 in Patients With AML or Higher Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Myeloid Leukemia Refractory | Higher Risk Myelodysplastic Syndromes

United States
Instituto Nacional de Cancer, Brazil

Not yet recruiting

PTCy and ATG for MSD and MUD Transplants

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma
Omeros Corporation

Recruiting

Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

Switzerland, Germany, Ukraine, United Kingdom
Longbio Pharma

Recruiting

A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants

Paroxysmal Nocturnal Hemoglobinuria (PNH)

China
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Myeloproliferative Neoplasm | Myelodysplastic Neoplasm | Pathway Mutant Myelodysplastic Syndromes

United States
Wuhan Union Hospital, China

Not yet recruiting

A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score

Myelodysplastic Syndromes
Peking University People's Hospital

Not yet recruiting

Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors

Myelodysplastic Syndromes | Acute Leukemia | Severe Aplastic Anemia
Sunnybrook Health Sciences Centre

Not yet recruiting

OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study (OURA MDS)

Myelodysplastic Syndromes | MDS

Canada
Ryvu Therapeutics SA

Recruiting

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (RIVER-52)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome

Poland
University of Alabama at Birmingham

Not yet recruiting

Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant

Myeloproliferative Disorders | Acute Leukemia | Myelodysplastic Syndrome

United States
Children's Oncology Group

Not yet recruiting

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Juvenile Myelomonocytic Leukemia
Ruijin Hospital

Recruiting

Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS

Myelodysplastic Syndromes | Myelodysplastic Syndrome With Excess Blasts-2 | Myelodysplastic Syndrome With Excess Blasts-1

China
GCP-Service International West GmbH
Saint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaborators

Not yet recruiting

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms ((MDS))

Low Risk Myelodysplastic Syndromes

Spain, Poland, Italy, Germany, France
Chengdu Suncadia Medicine Co., Ltd.

Recruiting

Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

China

Search clinical trials for: High-Risk Myelodysplastic Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations